Cost of care distribution in atrial fibrillation patients: the COCAF study

Abstract Background Atrial fibrillation (AF) currently represents a major economic burden for society. Very few studies have been performed to evaluate the cost of care for AF patients. This study is a large prospective survey designed to analyze the different cost drivers in the treatment of these patients. This survey, named Cost of Care in Atrial Fibrillation (COCAF), evaluated the cost of care for patients with AF treated by cardiologists in general office practice. Methods A group of 671 patients was recruited by 82 cardiologists distributed in all regions of France. The mean age of the patients was 69 years, and 64% were male. The mean follow-up was 329 ± 120 days. The costs of care were analyzed from the health care payer and the societal perspectives. Results During the follow-up period, 21 patients (3.13%) died and 210 (31.3%) patients were hospitalized. The number of hospitalizations and deaths was significantly higher in the group of persistent or permanent AF (PEAF) patients, as compared to paroxysmal AF (PAAF) patients. Hospitalizations were much more frequent in the PEAF group (127) than in the PAAF group (83, P P P P P P P Conclusions This prospective survey shows that hospitalizations represent the major cost driver in the treatment of AF patients. Outpatient care programs must be proposed to AF patients in order to avoid readmissions and to reduce the cost of treatment.

[1]  R B D'Agostino,et al.  Impact of atrial fibrillation on mortality, stroke, and medical costs. , 1998, Archives of internal medicine.

[2]  R. Thomson,et al.  Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation , 2000, The Lancet.

[3]  L. Shaw,et al.  Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. , 1997, The American journal of cardiology.

[4]  Mark L. Greenberg,et al.  Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation , 1999, Annals of Internal Medicine.

[5]  D K Owens,et al.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.

[6]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[7]  SamuelLévy,et al.  Characterization of Different Subsets of Atrial Fibrillation in General Practice in France , 1999 .

[8]  H. Liedholm,et al.  Health care costs of heart failure: results from a randomised study of patient education , 2000, European journal of heart failure.

[9]  S Capewell,et al.  Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996. , 2001, European heart journal.

[10]  G. Naccarelli,et al.  Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. , 1999, The American journal of cardiology.

[11]  R. Falk,et al.  Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. , 1998, Archives of internal medicine.

[12]  L. Frost,et al.  Decrease in mortality in patients with a hospital diagnosis of atrial fibrillation in Denmark during the period 1980-1993. , 1999, European heart journal.

[13]  S. Ebrahim,et al.  Cost-effectiveness of stroke prevention. , 2000, British medical bulletin.

[14]  M. Rosenqvist,et al.  Long‐Term Follow‐Up of Patients Treated By Radiofrequency Ablation of the Atrioventricular Junction , 1995, Pacing and clinical electrophysiology : PACE.

[15]  G. Naccarelli,et al.  Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. , 2000, The American journal of cardiology.

[16]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[17]  P. Kowey,et al.  Acute treatment of atrial fibrillation. , 1998, The American journal of cardiology.

[18]  E. Aliot,et al.  Second line pharmacological management of paroxysmal and persistent atrial fibrillation in france: a cost analysis. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  B. Norrving,et al.  Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. , 1992, BMJ.

[20]  S. Lévy,et al.  Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. , 1999, Circulation.